PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY
RR Barretoa, K Patelb, C Coombsc, N Shahd, T Eyree, W Wierdaf, P Ghiag, M Davidsh, W Jurczaki, A Matoj
a Eli Lilly and Company (Lilly), São Paulo, SP, Brazil
b Swedish Cancer Institute, Seattle, United States
c University of North Carolina at Chapel Hill, Chapel Hill, United States
d Medical College of Wisconsin, Milwaukee, United States
e Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom
f MD Anderson Cancer Center, Houston, United States
g Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
h Dana-Farber Cancer Institute and Harvard Medical School, Boston, United States
i Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
j Memorial Sloan Kettering Cancer Center, New York, United States
Ver másRead
1336
Timeswas read the article
544
Total PDF
792
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 7 | 12 | 4 | 16 |
| 2025 6 | 47 | 17 | 64 |
| 2025 5 | 64 | 14 | 78 |
| 2025 4 | 38 | 11 | 49 |
| 2025 3 | 46 | 13 | 59 |
| 2025 2 | 41 | 21 | 62 |
| 2025 1 | 33 | 23 | 56 |
| 2024 12 | 29 | 11 | 40 |
| 2024 11 | 27 | 18 | 45 |
| 2024 10 | 40 | 31 | 71 |
| 2024 9 | 41 | 19 | 60 |
| 2024 8 | 40 | 20 | 60 |
| 2024 7 | 46 | 24 | 70 |
| 2024 6 | 35 | 25 | 60 |
| 2024 5 | 40 | 21 | 61 |
| 2024 4 | 33 | 14 | 47 |
| 2024 3 | 24 | 24 | 48 |
| 2024 2 | 21 | 31 | 52 |
| 2024 1 | 12 | 11 | 23 |
| 2023 12 | 12 | 18 | 30 |
| 2023 11 | 15 | 21 | 36 |
| 2023 10 | 14 | 28 | 42 |
| 2023 9 | 11 | 20 | 31 |
| 2023 8 | 9 | 15 | 24 |
| 2023 7 | 9 | 6 | 15 |
| 2023 6 | 9 | 13 | 22 |
| 2023 5 | 9 | 13 | 22 |
| 2023 4 | 4 | 5 | 9 |
| 2023 3 | 4 | 6 | 10 |
| 2023 2 | 6 | 11 | 17 |
| 2023 1 | 5 | 4 | 9 |
| 2022 12 | 7 | 15 | 22 |
| 2022 11 | 6 | 11 | 17 |
| 2022 10 | 3 | 6 | 9 |
Show all
